SCHEMBL114205

SCHEMBL114205

CN1CCc2nc(N)sc2C1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAD52 P43351 3/20 0.63
RECQL P46063 1/20 0.63
GRM5 P41594 1/20 0.50
APOBEC3A P31941 1/20 0.48
APOBEC3G Q9HC16 1/20 0.48
DRD2 P14416 5/20 0.47
MAPT P10636 4/20 0.47
DRD3 P35462 4/20 0.47
LMNA P02545 2/20 0.47
ADRA2A P08913 2/20 0.47
ADRA2B P18089 2/20 0.47
ADRA2C P18825 2/20 0.47
HTR2A P28223 2/20 0.47
ADRA1A P35348 2/20 0.47
HRH1 P35367 2/20 0.47
OPRK1 P41145 1/20 0.47
HRH3 Q9Y5N1 1/20 0.47
KDM4E B2RXH2 5/20 0.46
ALDH1A1 P00352 5/20 0.46
CYP2C19 P33261 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL1253502 0.98 RAD52 (0.61) RAD52RECQLGRM5APOBEC3AAPOBEC3G
SCHEMBL3312725 0.89 RAD52 (0.55) RAD52RECQLGRM5APOBEC3AAPOBEC3G
SCHEMBL3312231 0.87 DRD2 (0.57) RAD52RECQLGRM5APOBEC3AAPOBEC3G
SCHEMBL9574602 0.85 RAD52 (0.50) RAD52RECQLAPOBEC3AAPOBEC3GDRD2
SCHEMBL8051769 0.79 GRM5 (0.51) RAD52RECQLGRM5MAPTHRH3
SCHEMBL209848 0.79 GRM5 (0.51) RAD52RECQLGRM5MAPTHRH3
SCHEMBL16870042 0.78 GRM5 (0.50) RAD52RECQLGRM5MAPTKDM4E
SCHEMBL10264057 0.78 RAD52 (0.58) RAD52RECQLAPOBEC3AAPOBEC3GDRD2
SCHEMBL15511829 0.78 RAD52 (0.58) RAD52RECQLAPOBEC3AAPOBEC3GDRD2
SCHEMBL13019235 0.78 GRM5 (0.50) RAD52RECQLGRM5MAPTHRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 271 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114507245-B Preparation method of idosiban and intermediate thereof 江苏丽源医药有限公司 2024-03-19 CN claimed
CN-117384186-A Synthesis method of intermediate for preparing edoxaban 沧州那瑞化学科技有限公司 2024-01-12 CN claimed
US-7880005-B2 reacting 5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine with an alkali metal nitrite in the presence of a reducing agent in an aqueous solution of an acidic compound; hydrolysis; industrial scale DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-02-01 US claimed
US-20100076192-A1 PROCESS FOR PRODUCING 5-METHYL-4,5,6,7-TETRAHYDROTHIAZOLO[5,4-c]PYRIDINE-2-CARBOXYLIC ACID DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2010-03-25 US claimed
US-12534474-B2 Dihydrofuropyridine derivatives as rho-kinase inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2026-01-27 US disclosed
EP-4263546-B1 DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS CHIESI FARM SPA (IT) 2025-07-02 EP disclosed
EP-4263547-B1 DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS CHIESI FARM SPA (IT) 2025-07-02 EP disclosed
WO-2024240118-A1 PREPARATION FOR AND USE OF HETEROARYL DERIVATIVES 广州智睿医药科技有限公司 2024-11-28 WO disclosed
CN-119019454-A Preparation and application of heteroaryl derivative 广州智睿医药科技有限公司 2024-11-26 CN disclosed
US-20240270747-A1 HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS GENENTECH, INC. (US) 2024-08-15 US disclosed
CN-117903166-A Novel ASK1 inhibitor and preparation method and application thereof 中国药科大学 2024-04-19 CN disclosed
US-20240092792-A1 DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2024-03-21 US disclosed
EP-1219609-B1 AROMATIC NITROGENOUS SIX-MEMBERED RING COMPOUNDS TANABE SEIYAKU CO (JP) 2007-04-04 EP disclosed
US-20070054897-A1 1,1-Dicyclohexyl-3-thiazol-2-yl-urea, 3-(5-Chloro-thiazol-2-yl)-1,1-dicyclohexyl-urea, for example; useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial, in particular, type 2 diabetes NOVO NORDISK A/S (DK) 2007-03-08 US disclosed
WO-2006114401-A2 NOVEL CYCLIC AMINES F. HOFFMANN-LA ROCHE AG (CH) 2006-11-02 WO disclosed
US-20060247238-A1 Cyclic amines F. HOFFMANN-LA ROCHE AG (CH) 2006-11-02 US disclosed
EP-1683800-A1 PROCESS FOR PRODUCING THIAZOLE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-07-26 EP disclosed
US-5656637-A SEROTONIN RECEIVER ANTAGONIST; PSYCHOLOGICAL DISORDERS YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 1997-08-12 US disclosed
US-5424431-A Shows selective agonistic activity for 5-HT3 receptor, useful drug for digestive disorder YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 1995-06-13 US disclosed
US-4289524-A Herbicidal 3-(tetrahydrobenzothiazol-2-yl)tetrahydro-1,3,5-oxadiazin-4-ones VELSICOL CHEMICAL COPORATION (US) 1981-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100076192-A1 PROCESS FOR PRODUCING 5-METHYL-4,5,6,7-TETRAHYDROTHIAZOLO[5,4-c]PYRIDINE-2-CARBOXYLIC ACID NOX4, NOX5, NOS2 RAD52 4640/4885RECQL 4770/4885GRM5 274/4885
US-20240092792-A1 DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS ROCK1, ROCK2, RHOA RAD52 4802/4885RECQL 2151/4885GRM5 1951/4885
US-12534474-B2 Dihydrofuropyridine derivatives as rho-kinase inhibitors ROCK1, RHOC, ROCK2 RAD52 4745/4885RECQL 1775/4885GRM5 3243/4885
US-20240270747-A1 HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS PDXK, BTK, TYK2 RAD52 816/4885RECQL 848/4885GRM5 2006/4885
US-20060247238-A1 Cyclic amines F12, F11, F2 RAD52 2876/4885RECQL 416/4885GRM5 3975/4885
US-20070054897-A1 1,1-Dicyclohexyl-3-thiazol-2-yl-urea, 3-(5-Chloro-thiazol-2-yl)-1,1-dicyclohexyl-urea, for example; useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial, in particular, type 2 diabetes GCK, GCKR, HK1 RAD52 4680/4885RECQL 3299/4885GRM5 2529/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.